Viemed Healthcare (NasdaqCM:VMD) FY Conference January 15, 2026 10:00 AM ET Company ParticipantsJoe Dorame - Managing DirectorTodd Zehnder - COOCasey Hoyt - CEOJoe DorameHello and welcome to the VieMed Healthcare Fireside Chat. My name is Joe Dorame, Managing Partner at Lytham Partners, and today I will be moderating a Q&A discussion with Casey Hoyt, Chief Executive Officer, and Todd Zehnder, Chief Operating Officer at VieMed, which trades on the Nasdaq under the ticker VMD. Let's get started. Casey and Tod ...

NEW YORK, Dec. 15, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Quipt Home Medical Corp. (NASDAQ: QIPT) related to its sale to affiliates of Kingswood Capital Management, LP. Under the terms of the p ...

Core Viewpoint - Quipt Home Medical Corp. reported strong financial results for Q4 and fiscal year 2025, highlighting organic growth and operational resilience despite industry challenges [5][6]. Financial Highlights - Q4 2025 revenue was $68.3 million, an 11% increase from $61.3 million in Q4 2024, with a sequential organic growth of 5% from Q3 2025 [6]. - Recurring revenue constituted 80% of total revenue in Q4 2025, driven by the resupply platform [6]. - Adjusted EBITDA for Q4 2025 was $14.9 million (21.8% of revenues), up from $13.4 million (21.9% of revenues) in Q4 2024, marking an 11% increase [6]. - Fiscal year 2025 revenue was $245.4 million, slightly down from $245.9 million in fiscal year 2024 [6]. - Adjusted EBITDA for fiscal year 2025 was $55.9 million (22.8% of revenue), compared to $57.7 million (23.5% of revenue) in fiscal year 2024, representing a 3% decrease [6]. - Net loss for Q4 2025 was ($3.6) million, or ($0.08) per diluted share, compared to a loss of ($2.9) million, or ($0.07) per diluted share in Q4 2024 [6]. - Net loss for fiscal year 2025 was ($10.7) million, or ($0.24) per diluted share, compared to ($6.8) million, or ($0.16) per diluted share in fiscal year 2024 [6]. - Cash flow from operating activities was $37.7 million for the year ended September 30, 2025, up from $35.4 million for the year ended September 30, 2024 [6]. - The company had $12.9 million in cash on hand as of September 30, 2025, compared to $11.3 million as of June 30, 2025 [6]. - The Net Debt to Adjusted EBITDA Leverage Ratio was 1.8x, indicating a conservative balance sheet [6][14]. Operational Highlights - The customer base increased by 10% year over year, serving 346,000 unique patients in fiscal year 2025 compared to 314,000 in fiscal year 2024 [6]. - Unique set-ups/deliveries rose to 917,000 in fiscal year 2025, a 7% increase from 854,000 in fiscal year 2024 [6]. - Respiratory resupply set-ups/deliveries increased by 1% to 486,000 in fiscal year 2025 from 480,000 in fiscal year 2024, attributed to technology and centralized intake processes [6].

Core Viewpoint - Quipt Home Medical Corp. has entered into a definitive agreement for acquisition by a special purpose acquisition vehicle, valuing the company at approximately US$260 million, with shareholders receiving US$3.65 per share in cash [1][2]. Transaction Details - The acquisition is an all-cash transaction with no financing conditions, funded by Kingswood Capital Management and Forager Capital Management [2]. - The transaction will result in Quipt becoming a privately held company, ceasing to report in the U.S. and Canada [2][11]. - The expected closing of the transaction is during the first half of 2026, subject to customary closing conditions [10]. Shareholder Value - The purchase price represents a 162% premium to Quipt's stock price on May 19, 2025, and a 54% premium to the 30-day volume-weighted average price (VWAP) as of December 12, 2025 [6][7]. - The transaction provides immediate liquidity and certainty of value to shareholders [6]. Board and Advisory Process - The Quipt Board of Directors, after a comprehensive review with financial advisors, unanimously recommends that shareholders vote in favor of the transaction [4]. - Fairness opinions from Truist and Evans & Evans confirmed that the transaction is fair from a financial perspective for Quipt shareholders [6][7]. Voting Support - Directors and executive officers holding approximately 11.4% of the shares have entered into Voting Support Agreements to vote in favor of the transaction [9]. - Forager Fund, LP, holding approximately 9.5% of the shares, has also agreed to vote in favor of the transaction [9]. Future Growth Potential - Kingswood and Forager expressed excitement about partnering with Quipt to support its next growth chapter as a private entity, focusing on expanding in strategic markets and investing in technology and clinical care [3].

Group 1 - AdaptHealth Corp. (AHCO) specializes in home medical equipment, healthcare supplies, and related in-home services [1] - The Zacks Consensus Estimate for AdaptHealth's current year earnings has been revised 13.1% downward over the last 60 days [1] - Alexander's, Inc. (ALX) is a real estate investment trust [1] - The Zacks Consensus Estimate for Alexander's current year earnings has been revised 5.5% downward over the last 60 days [1] Group 2 - Conagra Brands, Inc. (CAG) is a packaged food company [2] - The Zacks Consensus Estimate for Conagra's current year earnings has been revised 7.9% downward over the last 60 days [2]

Core Insights - Quipt Home Medical Corp. has successfully closed a joint venture transaction to acquire a 60% ownership interest in Hart Medical Equipment for a total consideration of $17.4 million, funded by senior credit facilities [1][4] - The acquisition is expected to enhance Quipt's presence in the Midwest, particularly in Michigan, and is aligned with the company's long-term growth strategy [1][3] - Hart Medical generated approximately $60 million in annual revenue and $7 million in Adjusted EBITDA for the twelve months ended June 2025, with expectations to generate over $10 million in annual Adjusted EBITDA in the next 6-9 months [4] Transaction Highlights - The joint venture includes three major health systems and two hospitals, collectively holding the remaining 40% interest in Hart [1] - Hart serves over 67,000 patients monthly, providing a stable and recurring revenue stream [4] - Quipt anticipates that Hart's Adjusted EBITDA margins will align with its historical corporate averages within the next 6-9 months [4] Management Commentary - The CEO of Quipt expressed excitement about the acquisition, highlighting Hart's strong health system relationships and regional market leadership as a strategic fit [3] - The CFO emphasized the disciplined approach to acquisitions and the company's ability to maintain a conservative leverage ratio while funding the transaction [3] - Hart's executive noted the importance of scale in the current healthcare environment and expressed confidence in the partnership with Quipt [5] Financial Expectations - Following the acquisition, Quipt's expected annualized run-rate revenue is projected to exceed $300 million, with anticipated Adjusted EBITDA exceeding $65 million post-integration of Hart [4] - The company plans to consolidate Hart's financial results for reporting purposes, reflecting its status as the primary beneficiary of the joint venture [4]

Core Viewpoint - Quipt Home Medical Corp. has received a new unsolicited acquisition proposal from Forager Capital Management, LLC at a price of US$3.10 per share, which follows previous offers that were deemed inadequate by the Company's Board [1][3]. Group 1: Acquisition Proposals - The latest proposal from FCM is a reduction from an earlier offer of US$3.90 per share made in January 2025, which represented a 26% premium over the current offer [2]. - The Board of Directors rejected the January Proposal, citing that it undervalued the Company and did not serve the best interests of shareholders [3]. - FCM has made multiple offers without engaging through the Company's financial advisor, raising concerns about its credibility and intentions [5]. Group 2: Company Developments - Since the January Proposal, the Company has made strategic acquisitions, including a full-service durable medical equipment provider with an unaudited revenue of US$6.6 million and a joint venture for a 60% stake in Hart Medical Equipment, contributing an additional unaudited revenue of US$60 million and US$7 million in Adjusted EBITDA [4]. - The Company aims to enhance shareholder value by expanding its service offerings in in-home monitoring and chronic disease management, focusing on patients with various health conditions [7]. Group 3: Board's Position - The Board, advised by Truist Securities, remains committed to protecting long-term shareholder value and is open to engaging with FCM if it complies with confidentiality agreements [6].

Financial Data and Key Metrics Changes - Revenue for fiscal Q3 2025 was $58.3 million, a decrease of 4.1% compared to $60.8 million in Q3 2024, but a return to positive quarter-over-quarter organic growth of 1.6% from $57.4 million in Q2 2025 [14][18] - Adjusted EBITDA for Q3 2025 was $13.7 million, or 23.5% of revenue, compared to $14.2 million, or 23.4% of revenue for Q3 2024, representing a 3.6% decrease [14][18] - Net loss for Q3 2025 was $3 million, or $0.07 per diluted share, compared to a loss of $1.6 million, or $0.04 per diluted share for Q3 2024 [15] - Cash flow from operations for the nine months ended June 30, 2025, was $27.9 million, compared to $25.4 million for the same period in 2024 [15] Business Line Data and Key Metrics Changes - The customer base decreased modestly to 151,000 unique patients as of June 30, 2025, from 153,000 unique patients as of June 30, 2024 [13] - Unique setups and deliveries totaled 210,000 in Q3 2025, down from 216,000 in Q3 2024 [13] - Respiratory resupply setups totaled 119,000 in Q3 2025, a slight decrease from 120,000 in the prior year quarter [13] Market Data and Key Metrics Changes - The company reported that recurring revenue for Q3 2025 remained strong at 81% of total revenue [14] - The joint venture with Heart Medical Equipment is expected to enhance the company's presence in the Midwest, particularly in Michigan and Ohio, with access to a recurring patient base of over 67,000 patients each month [20][28] Company Strategy and Development Direction - The company is focused on expanding its healthcare system partnerships, as evidenced by the recent transaction with Ballad Health and the joint venture with Heart Medical Equipment [5][19] - The strategic emphasis on respiratory care aligns with macro trends such as an aging population and rising chronic respiratory disease rates, which are expected to drive long-term demand [23][28] - The company aims to deepen referral networks and enhance operational efficiencies to capture a larger share of patient volume at the point of discharge [26][28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's operating metrics and the recent healthcare system transactions, indicating a clear roadmap for growth [9][21] - The company anticipates that the integration of recent acquisitions will lead to improved margins and operational efficiencies [42][44] - Management remains focused on maximizing long-term shareholder value while navigating the evolving healthcare landscape [29] Other Important Information - The company has entered into a joint venture to acquire a 60% ownership stake in Heart Medical Equipment, which generated approximately $60 million in revenue and $7 million in adjusted EBITDA as of June 30, 2025 [19][20] - The company reported a net debt to adjusted EBITDA leverage ratio of 1.5x, well within its target range [17] Q&A Session Summary Question: Can you discuss the adjusted EBITDA margin and targets for improvement? - Management expects continued improvements in EBITDA margins, despite patient CapEx being a drag due to investments in replacing ventilators [31][32] Question: How do you plan to increase the EBITDA margin for the Heart joint venture? - Management anticipates that integration will align Heart's cost structures with Quipt's historical averages, leading to margin improvements [34] Question: What types of patients are being discharged from the health centers? - The majority of patients are treated for respiratory conditions, including ventilation and oxygen needs [35] Question: Is there a financial component to the joint venture? - The joint venture involves an equity position, allowing the company to work closely with hospital systems to enhance discharge processes [38][40] Question: What is the current status of the M&A pipeline? - The M&A pipeline remains strong, with ongoing evaluations of strategic fits for future acquisitions [43][44]

Core Viewpoint - Quipt Home Medical Corp. is set to announce its fiscal Third quarter 2025 financial results on August 11, 2025, with a conference call scheduled for August 12, 2025, to discuss the results with the investment community [1][2]. Company Overview - Quipt Home Medical Corp. is a U.S.-based provider of home medical equipment, focusing on end-to-end respiratory care and in-home monitoring and disease management services [3]. - The company aims to expand its offerings to manage various chronic diseases, particularly targeting patients with heart or pulmonary diseases, sleep disorders, and reduced mobility [3]. - The primary business objective is to create shareholder value by providing a broader range of services to patients requiring in-home monitoring and chronic disease management [3]. - The organic growth strategy involves increasing annual revenue per patient by offering multiple services to the same patient and consolidating their services [3].

Core Viewpoint - The Schall Law Firm is investigating Quipt Home Medical Corp. for potential violations of securities laws, particularly concerning misleading statements and failure to disclose important information to investors [1][2]. Group 1: Investigation Details - The investigation centers on whether Quipt issued false or misleading statements, particularly regarding a press release on May 21, 2025, related to an acquisition offer from Forager Capital Management [2]. - Forager Capital Management, a significant shareholder, has requested Quipt to retract its misleading statement about their offer to acquire 100% of Quipt's common shares at a price of $3.10 per share [2]. - Following the news of the investigation and the press release from Forager, Quipt's shares experienced a decline of over 8.5% on the same day [2]. Group 2: Legal Representation - The Schall Law Firm is representing investors globally and specializes in securities class action lawsuits and shareholder rights litigation [3]. - Shareholders who have suffered losses are encouraged to contact the Schall Law Firm for a free discussion of their rights [3].